5055 May 2026 07:25
The 505(b)(2) regulatory pathway in the U.S. is a hybrid New Drug Application (NDA) route allowing manufacturers to rely on existing safety/efficacy data from approved drugs or public literature, rather than conducting entirely new studies. It streamlines approval for modified drugs (e.g., new formulations, dosages), reducing development costs and time, while offering potential market exclusivity. Key Advantage: It is a, faster, and more cost-effective alternative to a full 505(b)(1) NDA, and provides higher potential for market exclusivity (e.g., 3-5 years) compared to 505(j) generic approvals.